PhysIQ Elects Former Vice Admiral Raquel C. Bono, M.D. to Advisory Board

“Dr. Bono brings an impressive background consisting of distinguished military service, trauma surgery, and health care administration,” said Gary Conkright, physIQ’s CEO and co-founder. “She brings valuable knowledge and perspective for how healthcare delivery can leverage technology to improve outcomes and best leverage the healthcare assets for efficient deployment, and we are honored that she sees such promise in the role physIQ is playing to make that happen. We all believe that physIQ was a logical next step in Dr. Bono’s pursuit of healthcare excellence and we welcome her to the physIQ TEAM.”

Commissioned in June 1979, Dr. Bono obtained her bachelor’s degree from the University of Texas at Austin and MD from the School of Medicine at the Texas Tech University Health Sciences Center. She completed a surgical internship and a General Surgery residency at Naval Medical Center Portsmouth, and a Trauma and Critical Care fellowship at the Eastern Virginia Graduate School of Medicine in Norfolk, Virginia. She saw duty in Operations Desert Shield and Desert Storm and is the first female Navy medical officer to have achieved three-star rank. In addition, she is a Diplomate of the American Board of Surgery, also a Fellow of the American College of Surgeons and a member of the Eastern Association for the Surgery of Trauma. Her personal decorations include a Defense Superior Service Medal, three Legion of Merit Medals, two Meritorious Service Medals, and two Navy and Marine Corps Commendation Medals.

“Healthcare is undergoing a needed and dramatic change, accelerated by the COVID-19 pandemic, which illustrates how digital health and innovative technology, like physIQ’s, can improve outcomes more efficiently,” said Dr. Bono. “I am impressed with the role physIQ is playing to address the current pandemic and excited that my experience and skills will help physIQ’s mission to transform healthcare for all.”

This announcement builds on a big year for physIQ. Kicking off 2020, they announced the publication of their breakthrough LINK-HF study, which was published in Circulation – Heart Failure. This study, conducted with the U.S. Veteran’s Affairs, predicted Heart Failure hospitalization up to 10 days in advance. Following this, physIQ announced projects with the Department of Defense and the Henry M. Jackson Foundation for The Advancement of Military Medicine, as well as UI Health and the Chicago Medical Society to fight the COVID-19 pandemic. And most recently, physIQ was awarded a grant from the National Institutes of Health to develop an AI-based COVID-19 digital biomarker to address the rapid decline of high-risk COVID-19 patients.

About physIQ

PhysIQ is a leading digital medicine company dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its enterprise-ready cloud platform continuously collects and processes data from any wearable biosensor using a deep portfolio of FDA-cleared analytics. The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics. With applications in both healthcare and clinical trial support, physIQ is transforming continuous physiological data into insight for health systems, payers, and pharmaceutical companies.

For more information, please visit www.physIQ.com. Follow us on Twitter and LinkedIn.